Last Updated: November 16, 2026

Details for Patent: 10,781,218

« Back to Dashboard


Which drugs does patent 10,781,218 protect, and when does it expire?

Patent 10,781,218 protects KOMZIFTI and is included in one NDA.

This patent has forty-five patent family members in thirty-three countries.

Summary for Patent: 10,781,218
Title:Substituted inhibitors of menin-MLL and methods of use
Abstract:The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Inventor(s):Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
Assignee: Wellspring Biosciences LLC , University of Michigan System , Kura Oncology Inc
Application Number:US16/082,649
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

United States Patent 10,781,218: Scope, Claim Breadth, and US Patent Landscape Analysis

Executive summary: US Patent 10,781,218 claims a broad structural class of drug-like compounds defined by Formula (II-A) with wide latitude across core ring size (C), linker chemotypes (L2, L3), and multi-site substitution (R50, R51, R52, R53/R54, R56, RA/RB/RC), plus dependent claims that carve out specific subsets (e.g., heterocycles, saturation, and selected substituent sets). The independent claim’s drafting strategy is to capture numerous “implementation variants” (different ring/linker/surface chemistries) while maintaining a single umbrella structure. That breadth typically translates into high infringement surface area for later entrants that land anywhere inside the Formula (II-A) parameter space, but it also increases the risk that the claims are vulnerable to invalidity attacks if the specification is thin on exemplars across the full genus or if key limiting features are not supported.


What does US Patent 10,781,218 claim and how broad is Formula (II-A)?

Featured-snippet answer: The patent claims a genus: “A compound of Formula (II-A) (or salt)” where core (C) spans carbocycles and heterocycles, linkers (L2, L3) span many bond and functional connector types, and multiple substitution variables (R50, RA/RB/RC, R56, R59) permit extensive chemical diversity, with only a few explicit carve-outs (e.g., an exception when R56 = —CH3).

1) Independent claim architecture (Claim 1)

Claim 1 is structured around:

  • Core ring or scaffold (C):

    • Carbocycle: C3-12
    • Heterocycle: 3- to 12-membered heterocycle
    • Each is optionally substituted with an extensive list under R50.
  • Linker type (L2): includes a bond or heteroatom/functional connectors spanning:

    • —O—, —S—, —N(R51)—, —N(R51)CH2—
    • carbonyl and masked carbonyl families: —C(O)—, —C(O)O—, —OC(O)—, —OC(O)O—
    • amide/urea-like patterns: —C(O)N(R51)—, —C(O)N(R51)C(O)—, and larger variants
    • sulfonyl families: —S(O)2— and expanded S(O)2N(R51)—/N(R51)S(O)2—
    • alkyl/alkylene variants including alkylene, alkenylene, alkynylene, plus heteroanalogues.
  • Second linker (L3):

    • chosen from alkylene/alkenylene/alkynylene
    • each is substituted with R56 and optionally further substituted with R50.
  • Substituent system:

    • R1 and R3 each independently H or R50
    • R2 = R50
    • RA, RB, RC are each independently selected from R50 with allowance that two groups can form a bridge or ring.
  • Linker exponents:

    • m, n, p each independently integer 0 to 6.
  • Definition of R50 (substitution “alphabet”):

    • Includes standard medicinal chemistry functional groups:

      • halogen, nitro, cyano
      • OR/ SR (alkoxy/ thioether variants)
      • amines (N(R52)2, NR53R54), plus sulfonamide/sulfinamide-like moieties
      • carbonyl, esters, carboxylic acid derivatives
      • phosphonate variants (P(O)(OR52)2, P(O)(R52)2)
      • multiple unsaturations: ═O, ═S, ═N(R52)
    • Also permits carbocycles/heterocycles up to:

      • C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl
      • plus larger rings for substituents.
  • Definition of R51 and R56:

    • R51 is selected from substituent classes including acyl/alkoxycarbonyl and amino-acyl patterns:

      • —C(O)R52, —C(O)OR52, —C(O)N(R52)2, —C(O)NR53R54, plus
      • alkyl/alkenyl/alkynyl optionally substituted with the same large “alphabet,” and rings.
    • R56 is the key variable controlling L3 substitution; it spans:

      • same broad functional alphabet (including OR, carbonyls, sulfonyls, amino substituents, phosphonyl patterns)
      • and ring-forming connectivity: “R56 optionally forms a bond to ring C.”
      • plus restriction language: for compounds when R56 = —CH3, L3 is not further substituted with —OH, —NH2, or —CN.
  • Definition of R59:

    • R59 broadens the substitution of groups within some variable structures (appears in R56 definitions and other dependent constraints):
    • allows C1-20 alkyl/alkenyl/alkynyl and heteroalkyl/rings, with optional substitution.

2) Practical breadth assessment

From a freedom-to-operate perspective, Claim 1 is not a single scaffold with minor edits. It is closer to a parameterized combinatorial genus:

  • Core ring size and heteroatom incorporation are fully programmable (C3-12, 3–12 heterocycles).
  • Linkers cover multiple chemical families (ether/sulfide/amine linkers; amide-like; sulfone-like; alkyl/alkenyl/alkynyl).
  • Multiple substitution vectors are allowed simultaneously (R50 on multiple sites; R56 on L3 and sometimes bonding to ring C; RA/RB/RC enabling ring-closure/bridging).
  • Dependent claims (Claims 2–20) then prune some parameter ranges but still keep meaningful coverage.

Which dependent claims narrow the genus and what subsets do they target?

H2: Which dependent claims narrow US 10,781,218 to specific ring/linker/substitution subsets?

Featured-snippet answer: Dependent claims add specific restrictions on:

  • Rc allowed forms (Claim 2)
  • C ring class (Claim 3)
  • C within additional “R57” type (Claim 4 excerpt)
  • R2/R3 specific selection rules (Claim 5)
  • R1 haloalkyl (Claim 6)
  • m, n, p numeric limitations (Claims 7–9)
  • L3 substitution patterns (Claim 10)
  • R56 fixed to methyl (Claim 12)
  • plus a stereochemical requirement and formulas II-C/II-F/II-H (Claims 15–17).

Key narrowing points by claim number

  • Claim 2 (Rc constraints): Rc limited to a subset including:

    • —C(O)R52, sulfur oxidation states: —S(=O)R52, —S(=O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54
    • amino-sulfide form: “NR52S(—O)2R52”
    • ═O and small alkyl/haloalkyl (C1-3)
    • or two RC groups can form a C1-3 bridge.
  • Claim 3 (core ring C):

    • “C is 5- to 12-membered saturated heterocycle with at least one nitrogen atom.”
    • This is a clear genus-to-subgenus conversion toward saturated N-heterocycles.
  • Claim 5 (R2 and R3 options):

    • R2 limited to:
      • H, halogen, OH, OR52, NH2, N(R52)2, CN
      • C1-3 alkyl and C1-3 alkyl-N(R52)2
      • C1-3 haloalkyl
      • C2-3 alkenyl and C2-3 alkynyl
    • R3 limited to:
      • H, halogen, OH, N(R52)2, CN
      • —C(O)OR52
      • C1-3 alkyl and C1-3 haloalkyl
  • Claim 6 (R1):

    • R1 is C1-3 haloalkyl.
  • Claims 7–9 (integer constraints):

    • Claim 7: m = 0
    • Claim 8: n = 1–3
    • Claim 9: L2 is C1-4 alkylene, optionally substituted with R50.
  • Claim 10 (L3 substitution set):

    • L3 substituted with one or more from:
      • =O
      • C1-6 alkyl, C1-6 haloalkyl
      • “C1-3 alkyl(cyclopropyl)”
      • “C1-3 alkyl(NR52C(O)R52)”
      • “—O(C1-6 alkyl)”
  • Claim 12 (R56 methyl):

    • “Wherein R56 is methyl.”
  • Claim 13 and 14 (more specific L2/L3/R56/R59/p/Rc):

    • Claim 13 sets:
      • L2 among —O—, —S—, —NH—, —CH2—
      • L3 among C1-6 alkylene/ C2-6 alkenylene/ C2-6 alkynylene, each substituted with one or more R56 and optionally further substituted with R50
      • m=0–3, n=1–3, p=0–6
      • R56 limited to narrower choices: —OR59, =O, and C1-10 alkyl/ C2-10 alkenyl/ C2-10 alkynyl (with substitutable variants)
      • and R56 may form a bond to ring C
    • Claim 14 then sets:
      • p = 1 and RC limited to sulfonyl/sulfonamide subset (—S(=O)2R52, —S(=O)2N(R52)2, or —S(=O)2NR53R54).
  • Claim 15 (stereochemistry):

    • “compound is a stereoisomer provided in at least 90% enantiomeric excess.”
  • Claims 16–17 (embedded structural formulas):

    • Claim 16 references “Formula (II-C)”
    • Claim 17 references “Formula (II-F) or Formula (II-H)”
    • These dependent clauses usually correspond to specific embodiments within the broader parameter space.
  • Claim 18–19 (selection lists):

    • Claim 18 and 19 are truncated in the prompt but indicate further “selected from the group consisting of …” and “or pharmaceutically acceptable salt thereof,” implying explicit compound enumerations.
  • Claim 20 (composition):

    • a pharmaceutical composition using the claimed compound plus a pharmaceutically acceptable carrier.

What parts of the independent claim drive infringement risk?

H2: Which claim elements create the largest infringement surface area under US 10,781,218?

Featured-snippet answer: The infringement surface area is driven by the independent claim’s “open-ended” definitions of C (ring size), L2 (linker chemotypes), L3 substitution (R56 with optional bonding to ring C), and the substituent sets (R50/R51/R52/R53/R54/R59). Dependent claims narrow those freedoms but do not eliminate the base coverage.

1) C (3–12 carbocycles/heterocycles)

A wide C definition means an accused compound does not need an exact core identity. It needs only to land within:

  • carbocycle size 3–12; or
  • heterocycle size 3–12.

That supports broad coverage against structurally varied analogs.

2) L2 linker is highly permissive

L2 includes:

  • direct bond
  • heteroatom linkers (O, S, N substituted by R51)
  • carbonyl-adjacent and ester-like linkers
  • sulfonyl-bridged patterns
  • plus alkyl/alkenyl/alkynyl/heteroalkylene variants.

Any generic design that keeps the backbone but swaps linker chemistry is still likely to fall within Claim 1.

3) L3 and R56 are the key “diversification valve”

  • L3 is substituted with R56 and optionally with R50
  • R56 can optionally bond to ring C, creating ring-closure outcomes
  • The special carve-out is narrow: when R56 = —CH3, L3 cannot further have —OH, —NH2, or —CN. That is a targeted exclusion, but only for methyl at that position.

4) R50/R51/R56 substitution alphabets are large

The definitions permit:

  • halogen, nitro, cyano
  • OR/SR
  • primary/secondary/tertiary amine patterns (via N(R52)2 etc.)
  • sulfonamide/sulfone motifs
  • carbonyl/ester/carboxyl derivatives
  • phosphonate (P(O)(OR52)2 / P(O)(R52)2)
  • and ring-containing substituents.

That is a common signature of a genus claim intended to cover multiple medicinal-chemistry “series” under one umbrella.


What patent landscape questions matter for this patent specifically?

H2: How many other US patents typically cover the same compound class as 10,781,218?

Featured-snippet answer: The prompt provides only the claim set and does not include bibliographic data (inventor, assignee, application number, filing/priority dates, specification title, or listed related patents). Without those, the number of related US continuations, divisional claims, and overlapping family members cannot be determined from the provided material.

H2: What patent expiration dates apply to US 10,781,218 and its family?

Featured-snippet answer: Expiration dates depend on priority and filing timeline under 35 USC 154, plus any PTA adjustments and terminal disclaimers. Those dates are not provided in the prompt and cannot be derived from claim text alone.

H2: What is the Orange Book status of US 10,781,218?

Featured-snippet answer: Orange Book listing requires the drug name/NDA/BLA, which is not included in the prompt. Claim scope alone does not map to Orange Book status.

H2: Which companies are challenging patents like 10,781,218 through Paragraph IV?

Featured-snippet answer: Paragraph IV challenges are tied to specific ANDA products and listed patents. The prompt includes no NDA/ANDA/BLA identifiers or litigation captions.


How strong is the patent estate implied by the claim drafting?

H2: How strong is the patent estate for the Formula (II-A) compound class?

Featured-snippet answer: Claim strength based on drafting alone is mixed: breadth is high (genus capture), but the enforceability of such breadth hinges on whether the specification supports the full parameter space with disclosure across the “alphabet” of functional groups, linker variants, and core chemotypes. The claim includes many alternatives, creating a typical enablement and written description pressure point.

1) Written description and enablement pressure points

High genuses with:

  • wide ring size
  • broad linker sets
  • large substituent alphabets (R50/R51/R52/R53/R54/R59)
  • optional bond formations (R56 to ring C)

often increase the challenge that the patent must show possession and enablement for substantially all covered combinations.

2) Litigation leverage points

From a litigation/infringement standpoint, the independent claim’s parameterized language is favorable for plaintiff-side claim construction because it provides:

  • many routes to match without requiring exact structural identity
  • and explicit inclusion of multiple functional connector types.

From a defense standpoint, the same language can enable a narrowing construction argument by emphasizing that certain alternatives require specific internal relationships not captured in the accused compound.


What generic entry risks exist under this claim scope?

H2: What generic entry risks exist for compounds that differ only by linker or substituent choices?

Featured-snippet answer: Risk is elevated for “nearby” analogs because Claim 1 is written to include many substitutions and linker chemotypes. A generic candidate that stays within:

  • C3-12 core ring sizes
  • allowed L2 and L3 chemistries
  • and permissible R50/R56 substitution ranges

is structurally exposed, even if it uses a different representative functional group choice.

1) Common “design-around” levers and how Claim 1 responds

  • Changing the core ring to another valid 3–12 carbocycle/heterocycle: still potentially captured.
  • Swapping O/S/amide/sulfonyl linkers within L2: still potentially captured.
  • Changing the substituent on L3 to a small group like methyl: only one narrow carve-out exists when R56 = —CH3 regarding additional —OH/—NH2/—CN on L3; other substituents remain covered.

2) Where design-around may be more plausible

The largest plausible avoidance vectors (not confirmed without the missing formula structures) would be:

  • moving outside the defined L2/L3 selection sets,
  • moving outside allowable ring size or saturation constraints (depending on dependent claims),
  • or achieving a substituent pattern outside the defined R50/R56 alphabets. But the prompt does not supply the detailed structures of II-A or the specific embodiment lists in Claims 18–19, so these cannot be asserted concretely.

Key Takeaways

  • US Patent 10,781,218 claim 1 is a broad genus defined by Formula (II-A) with extensive variation across core ring (C), linkers (L2, L3), and substitution families (R50, R51, R52, R53/R54, R56, R59).
  • Dependent claims tighten the genus using ring class selection, specific numeric limitations, and restricted substituent sets, with an additional stereochemistry requirement in Claim 15.
  • The drafting is plaintiff-friendly for infringement theory because it enumerates many functional chemotypes. The enforceability of that breadth is specification-dependent, with typical genus-related risks around written description and enablement.

FAQs

  1. Does Claim 1 cover salts, and are different salt forms likely separately enforceable?
    Claim 1 expressly covers “pharmaceutically acceptable salt thereof,” including salts generally treated as equivalent for infringement purposes.

  2. Which positions in the claim drive chemical diversity the most: C, L2, L3, or R50/R56?
    The breadth is driven by C (ring size class), L2 (linker chemotypes), and L3 substitution via R56, with R50 expanding substitution across sites.

  3. Is there a specific limitation when R56 is methyl?
    Yes. If R56 = —CH3, L3 is not further substituted with —OH, —NH2, or —CN.

  4. Can dependent claims require specific stereochemical purity?
    Yes. Claim 15 requires a stereoisomer with at least 90% enantiomeric excess.

  5. Does the patent include composition claims in addition to compound claims?
    Yes. Claim 20 is a pharmaceutical composition claim covering a claimed compound plus a pharmaceutically acceptable carrier.


References

  1. US Patent 10,781,218 (provided claim text).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,781,218

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kura KOMZIFTI ziftomenib CAPSULE;ORAL 220305-001 Nov 13, 2025 RX Yes Yes 10,781,218 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.